dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Diener, Hans Christoph |
dc.contributor.author | Ashina, Messoud |
dc.contributor.author | Durand-Zaleski, Isabelle |
dc.contributor.author | Kurth, Tobias |
dc.contributor.author | Lantéri-Minet, Michel |
dc.contributor.author | Lipton, Richard B |
dc.contributor.author | Pozo Rosich, Patricia |
dc.date.accessioned | 2021-06-29T11:00:46Z |
dc.date.available | 2021-06-29T11:00:46Z |
dc.date.issued | 2021-03 |
dc.identifier.citation | Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lantéri-Minet M, Lipton RB, et al. Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia. 2021 Mar;41(3):279–293. |
dc.identifier.issn | 1468-2982 |
dc.identifier.uri | https://hdl.handle.net/11351/6103 |
dc.description | Acute therapy; Migraine; Preventive treatment |
dc.description.abstract | The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Cephalalgia;41(3) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tecnologia mèdica - Avaluació |
dc.subject | Migranya - Prevenció |
dc.subject.mesh | Migraine Disorders |
dc.subject.mesh | /prevention & control |
dc.subject.mesh | Technology Assessment, Biomedical |
dc.title | Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/0333102421989247 |
dc.subject.decs | trastornos migrañosos |
dc.subject.decs | /prevención & control |
dc.subject.decs | evaluación de tecnologías biomédicas |
dc.relation.publishversion | https://journals.sagepub.com/doi/10.1177/0333102421989247 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Diener HC] Institute for Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Essen, Berlin, Germany. [Ashina M] Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark. [Durand-Zaleski I] Université de Paris, CRESS, INSERM, INRA, URCEco, AP-HP, Hôpital de l'Hôtel Dieu, Paris, France. Santé Publique Hôpital Henri Mondor, Créteil, France. [Kurth T] Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany. [Lantéri-Minet M] Départment d'Evaluation et Traitement de la Douleur, CHU de Nice, FHU InovPain, Universite Cete Azur, Nice, France. [Lipton RB] Albert Einstein College of Medicine, Bronx, NY, USA. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Headache Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 33472427 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |